As­traZeneca sells two COPD drugs to a fa­mil­iar part­ner as Pas­cal So­ri­ot's on­col­o­gy push march­es on

As CEO Pas­cal So­ri­ot con­tin­ues his long-run­ning piv­ot to­ward on­col­o­gy, As­traZeneca is of­fload­ing an­oth­er pair of res­pi­ra­to­ry drugs.

The drug­mak­er is sell­ing off two med­i­cines con­tain­ing the ac­tive in­gre­di­ent acli­dini­um bro­mide to Co­vis Phar­ma Group, the com­pa­nies an­nounced Mon­day morn­ing, and re­ceiv­ing $270 mil­lion in re­turn. Co­vis will al­so cov­er on­go­ing de­vel­op­ment costs for the drugs, which are mar­ket­ed as Tu­dorza and Du­ak­lir in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER